Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT05124249
Recruiting Observational

Imaging and Physiologic Evaluation of Coronary Artery Disease

NCT05124249 · tracked via the Priya Life Science South Korea tracker
Sponsor
Chonnam National University Hospital
Phase
Observational
Started
2021-11-01
Last updated
2026-03-18

Condition(s) studied

Ischemic Heart DiseaseAtherosclerosis

Investigational drug(s) / intervention(s)

Intravascular imaging (IVUS or OCT) or Invasive physiologic assessmentPCI

Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment: Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment

PCI: Patients who undergoing PCI

Study summary

To evaluate the long-term clinical outcomes and prognostic factors in patients with coronary artery disease (CAD) undergoing invasive coronary angiography (ICA), intravascular imaging, or invasive physiologic assessment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Subject must be at least 18 years of age * Subjects who suspected ischemic heart disease and underwent ICA. * Subjects who were performed intravascular imaging or invasive physiologic assessment Exclusion Criteria: * Subject with Age \<18 years * Pregnant women

Primary outcome measure(s)

  • MACE — 3-Year after the index procedure
    a composite of all-cause death, myocardial infarction, or any revascularization

Trial sites (1)

FacilityCityRegionStatus
Chonnam National University Hospital Gwangju South Korea Recruiting

More Chonnam National University Hospital trials in South Korea

Abbreviated Antithrombotic Therapy After PCI in Patients With AF and AMI Recruiting
Timing of FFR-guided PCI for Non-IRA in NSTEMI and MVD (OPTION-NSTEMI) Recruiting
Long-term Clinical Outcomes After Retinal Artery Occlusion Recruiting
Optimal Timing of Microaxial Flow Pump(Impella CP) in AMI-related Cardiogenic Shock Starting soon
Psychopharmacotherapy for Depressive Patients Recruiting

Other trials for the same condition

Guideline Oriented Approach To Lipid Lowering In Asia-Pacific Recruiting
Impact of Dynamic CoROnary RoADmap System for Guidance of Instantaneous Wave-Free Ratio or Fractional Flow Reserve Recruiting
Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia Recruiting
Clopidogrel Versus Aspirin MOnotherapy After 1- to 3-month of Dual-antiplatelet thErapy Following Zotarolimus-eluting Onyx Stents Implantation; C-MODE Trial Recruiting
Clopidogrel Versus Cilostazol on Vessels Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05124249 on ClinicalTrials.gov ↗ ← All trials in South Korea